HSBC Holdings’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
BBA
KCM
HSBC Holdings's SMMT Position: Q3 2026 in Review
HSBC Holdings reduced its Summit Therapeutics (SMMT) stake by 47% in Q3 2026, selling an estimated $848K and leaving 63,856 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1897.
HSBC Holdings first reported a position in SMMT in Q1 2020 and has held it in 8 quarters since. The position peaked at $1.78M in Q2 2026. 294 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- HSBC Holdings held 63,856 shares of Summit Therapeutics worth $1.1M as of Q3 2026.
- HSBC Holdings sold 56,704 Summit Therapeutics shares in Q3 2026, an estimated $848K.
- Summit Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q3 2026, its #1897 holding.
- HSBC Holdings first reported a position in Summit Therapeutics in Q1 2020 and has held it in 8 quarters since.
- HSBC Holdings's Summit Therapeutics position peaked at $1.78M in Q2 2026.
- 294 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on HSBC Holdings's 13F filing for Q3 2026, filed 16 Nov 2026.